Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 8, 2013, Pages

  Schlaak, Max ^a   Pickenhain, Juliane ^a   Theurich, Sebastian ^a   Skoetz, Nicole ^a   von Bergwelt Baildon, Michael ^a   Kurschat, Peter ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; DOXORUBICIN; GEMCITABINE; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; MORTALITY; OVERALL SURVIVAL; PATIENT SAFETY; PHOTOPHERESIS; PRIMARY TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TRANSPLANTATION CONDITIONING; TREATMENT RESPONSE; ULTRAVIOLET IRRADIATION; ALLOTRANSPLANTATION; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS; STEM CELL TRANSPLANTATION; SKIN TUMOR;

HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 84893359682     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD008908.pub3     Document Type: Review

References (80)

1. Alaibac M, Berti E, Pigozzi B, Chiarion V, Aversa S, Marino F, et al. High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphoma. Journal of the American Academy of Dermatology 2005;52(5 Suppl 1):121-3. [PUBMED: 15858508]
2. Bertz H, Illerhaus G, Veelken H, Finke J. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Annals of Oncology 2002;13(1):135-9. [PUBMED: 11863095]
3. Burt RK, Guitart J, Traynor A, Link C, Rosen S, Pandolfino T, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplantation 2000;25(1):111-3. [PUBMED: 10654025]
4. Chanan-Khan A, Islam T, Alam A, Miller KC, Gibbs J, Barcos M, et al. Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leukemia & Lymphoma 2004;45(8):1673-5. [PUBMED: 15370223]
5. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20(9):1533-8. [PUBMED: 16871285]
6. Cudillo L, Cerretti R, Baliva G, De Angelis G, Postorino M, Picardi A, et al. Sézary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion. Bone Marrow Transplantation 2009;43(4):347-8. [PUBMED: 18850017]
7. Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplantation 2008;41(7):597-604. [PUBMED: 18176611]
8. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 2010;28(29):4492-9. [PUBMED: 20697072]
9. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sézary syndrome. Journal of Clinical Oncology 2010;28(14):2365-72. [PUBMED: 20351328]
10. Fijnheer R, Sanders CJ, Canninga MR, de Weger RA, Verdonck LF. Complete remission of a radiochemotherapy-resistant cutaneous T-cell lymphoma with allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplantation 2003;32(3):345-7. [PUBMED: 12858211]
11. Gabriel IH, Olavarria E, Jones RR, Whittaker S, Chaidos A, Apperley JF. Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides. Bone Marrow Transplantation 2007;40(4):401-3. [PUBMED: 17589536]
12. Ghobrial IM, Weenig RH, Pittlekow MR, Qu G, Kurtin PJ, Ristow K, et al. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leukemia & Lymphoma 2005;46(5):703-8. [PUBMED: 16019507]
13. Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Archives of Dermatology 2002;138(10):1359-65. [PUBMED: 12374543]
14. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biology of Blood & Marrow Transplantation 2008;14(4):480-3. [PUBMED: 18342792]
15. Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clinical Lymphoma & Myeloma 2007;7(8):541-5. [PUBMED: 18021473]
16. Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplantation 2004;34(6):521-5. [PUBMED: 15286686]
17. HoffNP, Groffik A, Mota R, Pippirs U, Hengge UR, Kobbe G, et al. Successful use of allogeneic stem cell transplantation for treatment-refractory mycosis fungoides [Erfolgreicher Einsatz einer allogenen Stammzelltransplantation bei therapierefraktärer Mycosis fungoides]. Hautarzt 2008;59(10):779-82. [PUBMED: 18773178]
18. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage-based approach. Journal of the National Comprehensive Cancer Network 2008;6(4):436-42. [PUBMED: 18433609]
19. Ichii M, Hatanaka K, Imakita M, Ueda Y, Kishino B, Tamaki T. Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor. Leukemia & Lymphoma 2006;47(10):2250-2. [PUBMED: 17071503]
20. Kahata K, Hashino S, Takahata M, Fujisawa F, Kondo T, Kobayashi S, et al. Durable remission of Sézary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning. Acta Haematologica 2008;120(1):14-8. [PUBMED: 18716396]
21. Knobler R, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Annals of the New York Academy of Sciences 2001;941:123-38. [PUBMED: 11594566]
22. Knobler E, Warmuth I. Extracorporeal photochemotherapy: a case report and update. Cutis 2002;69(2):119-23. [PUBMED: 11868976]
23. Koch R, Jaffe ES, Mensing C, Zeis M, Schmitz N, Sander CA. Cutaneous gamma/delta T-cell lymphoma [Primär kutanes Gamma/Delta-T-Zell-Lymphom]. Journal der Deutschen Dermatologischen Gesellschaft 2009;7(12):1065-7. [PUBMED: 19694889]
24. Majhail NS, Burns LJ. Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas. Current Hematology Reports 2005;4(4):252-9. [PUBMED: 16009039]
25. Masood N, Russell KJ, Olerud JE, Sabath DE, Sale GE, Doney KC, et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. Journal of the American Academy of Dermatology 2002;47(1):140-5. [PUBMED: 12077596]
26. Molina A, Nademanee A, Arber DA, Forman SJ. Remission of refractory Sézary syndrome after bone marrow transplantation from a matched unrelated donor. Biology of Blood & Marrow Transplantation 1999;5(6):400-4. [PUBMED: 10595818]
27. Molina A, Zain J, Arber DA, Angelopolou M, O'Donnell M, Murata-Collins J, et al. Durable clinical, cytogenetic and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sézary syndrome and mycosis fungoides. Journal of Clinical Oncology 2005;23(25):6163-71. [PUBMED: 16135483]
28. Mukai HY, Okoshi Y, Shimizu S, Katsura Y, Takei N, Hasegawa Y, et al. Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation. European Journal of Haematology 2003;70(6):413-6. [PUBMED: 12756026]
29. Nakahashi H, Tsukamoto N, Yamane A, Saitoh T, Uchiumi H, Handa H, et al. Autologous peripheral blood stem cell transplantation to treat CHOP-refractory aggressive subcutaneous panniculitis-like T cell lymphoma. Acta Haematologica 2009;121(4):239-42. [PUBMED: 19556752]
30. Nishio M, Koizumi K, Endo T, Takashima H, Haseyama Y, Fujimoto K, et al. Effective high-dose chemotherapy combined with CD34+-selected autologous peripheral blood stem cell transplantation in a patient with cutaneous CD30-negative large T cell lymphoma. Bone Marrow Transplantation 2000;25(12):1315-7. [PUBMED: 10871740]
31. Okada S, Nannya Y, Ota S, Takazawa Y, Yamamoto G, Kumano K, et al. Cutaneous T-cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant. British Journal of Dermatology 2010;162(1):229-30. [PUBMED: 19903173]
32. Perez-Persona E, Mateos-Mazon JJ, Lopez-Villar O, Arcos MJ, Encinas C, Graciani IF, et al. Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation. Bone Marrow Transplantation 2006;38(12):821-2. [PUBMED: 17057727]
33. Poligone B, Heald P. Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard. Dermatologic Clinics 2010;28(3):501-10. [PUBMED: 20510760]
34. Rook AH, Wolfe JT. Role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. Journal of Clinical Apheresis 1994;9(1):28-30. [PUBMED: 8195109]
35. Russell-Jones R, Child F, Olavarria E, Whittaker S, Spittle M, Apperley J. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Annals of the New York Academy of Sciences 2001;941:147-54. [PUBMED: 11594568]
36. Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. British Journal of Haematology 2010;150(2):170-8. [PUBMED: 20507311]
37. Soligo D, Ibatici A, Berti E, Morandi P, Longhi E, Venegoni L, et al. Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplantation 2003;31(8):663-6. [PUBMED: 12692606]
38. Taylor A, Gasparro FP. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma and other diseases. Seminars in Hematology 1992;29(2):132-41. [PUBMED: 1594945]
39. Tsuji H, Wada T, Murakami M, Kashiwagi T, Ito Y, Ishida-Yamamoto A, et al. Two cases of mycosis fungoides treated by reduced-intensity cord blood transplantation. Journal of Dermatology 2010;37(12):1040-5. [PUBMED: 21083707]
40. Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biology of Blood & Marrow Transplantation 2009;15(8):982-90. [PUBMED: 19589488]
41. Zain J, Kaminetzky D, O'Connor OA. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. Expert Review of Hematology 2010;3(2):187-203. [PUBMED: 21083462]
42. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19(12):2304-12. [PUBMED: 16193083]
43. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. American Journal of Clinical Dermatology 2002;3(3):193-215. [PUBMED: 11978140]
44. Dearden C. Is there a role for hemopoietic stem-cell transplantation in CTCL?. Oncology (Williston Park, N.Y.) 2007;21(2 Suppl 1):24-8. [PUBMED: 17474356]
45. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
46. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
47. Feinstein L, Storb R. Nonmyeloablative hematopoietic cell transplantation. Current Opinion in Oncology 2001;13(2):95-100. [MEDLINE: 11224706]
48. Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K, et al. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant 2004;33(9):881-9. [PUBMED: 14990986]
49. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Current Opinion in Oncology 2009;21(2):131-7. [PUBMED: 19532014]
50. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97(3):631-7. [PUBMED: 11157478]
51. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
52. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
53. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
54. HoffNP, Bruch-Gerharz D. The role of hematopoietic stem-cell transplantation in cutaneous T-cell lymphoma. Giornale Italiano di Dermatologia e Venereologia 2010;145(3):345-59. [PUBMED: 20461043]
55. Introcaso CE, Leber B, Greene K, Ubriani R, Rook AH, Kim EJ. Stem cell transplantation in advanced cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 2008;58(4):645-9. [PUBMED: 18258335]
56. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biology of Blood and Marrow Transplantation 2008;14(9 Suppl):8-15. [PUBMED: 18721775]
57. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Archives of Dermatology 2003;139(7):857-66. [PUBMED: 12873880]
58. Knobler E. Current management strategies for cutaneous T-cell lymphoma. Clinics in Dermatology 2004;22(3):197-208. [PUBMED: 15262305]
59. Koeppel MC, Stoppa AM, Resbeut M, Blaise D, Coignet M, Coulier L, et al. Mycosis fungoides and allogenic bone marrow transplantation. Acta Dermato-Venereologica 1994;74(4):331-2. [PUBMED: 7976105]
60. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sanguinis 1998;74(Suppl 2):321-9. [PUBMED: 9704463]
61. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112(12):4371-83. [PUBMED: 19029455]
62. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010;70(3):273-86. [PUBMED: 20166766]
63. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333(7568):597-600.
64. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
65. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation 2010;45(2):219-34. [PUBMED: 19584824]
66. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
67. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
68. Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft-versus-cancer effect. British Journal of Haematology 2009;147(5):614-33. [PUBMED: 19735262]
69. Rocha V, Mohty M, Gluckman E, Rio B, Eurocord, Reduced-Intensity Conditioning Subcommittee of the Acute Leukaemia Working Party, French Society of Bone Marrow Transplantation and Cellular Therapy. Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies. Current Opinion in Oncology 2009;21(Suppl 1):31-4. [PUBMED: 19561411]
70. Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opinion on Biological Therapy 2011;11(4):473-87. [PUBMED: 21269237]
71. Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T-cell lymphoma in Norway. The British Journal of Dermatology 2009;160(2):376-9. [PUBMED: 18808419]
72. Stadler R, Assaf C, Klemke CD, Nashan D, Weichenthal M, Dummer R, et al. Short German guidelines: cutaneous lymphomas. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG 2008;6 Suppl 1:S25-31. [PUBMED: 18801140]
73. Stang A, Streller B, Katalinic A, Lehnert M, Eisinger B, Kaatsch P, et al. Incidence of skin lymphoma in Germany. Annals of Epidemiology 2006;16(3):214-22. [PUBMED: 16019225]
74. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
75. Storb R. Reduced-intensity conditioning transplantation in myeloid malignancies. Current Opinion in Oncology 2009;21(Suppl 1):3-5. [PUBMED: 19561410]
76. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
77. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. International Journal of Dermatology 2009;48(3):243-52. [PUBMED: 19261011]
78. Wheatley K, Gray R. Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. International Journal of Epidemiology 2004;33(1):15-7. [PUBMED: 15075139]
79. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. The British Journal of Dermatology 2003;149(6):1095-107. [PUBMED: 14696593]
80. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sézary syndrome variants of cutaneous T-cell lymphoma. Cancer Treatment Reviews 2007;33(2):146-60. [PUBMED: 17275192]